We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

By LabMedica International staff writers
Posted on 06 Mar 2023
Print article
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil differ significantly amongst them, with some experiencing good, long-term responses but others receiving no benefits as their cancers become resistant to each treatment. Now, researchers have discovered that a genetic test, an established part of standard care in the UK and globally to predict patients' responses to other targeted cancer drugs, can also predict whether chemotherapy will work for bowel cancer patients. This discovery could aid in sparing patients from unnecessary toxicity and debilitating side effects by avoiding treatments that will not benefit them.

A team of researchers, including investigators from Imperial College London (London, UK), has discovered that a particular mutation - referred to as KRASG12 - in the KRAS gene is linked to a lower survival rate in treated patients. On the other hand, another mutation was found to be associated with a three-fold increase in survival. The study's results suggest that patients with KRASG12 mutations - constituting nearly 28% of all bowel cancer patients - gain no benefit from trifluridine/tipiracil and should consider partaking in clinical trials rather than enduring unnecessary toxicity. Conversely, patients without KRAS mutations may benefit from trifluridine/tipiracil, while those with a KRASG13 mutation are likely to respond well to treatment.

As part of standard NHS care, patients with advanced bowel cancer are already given gene tests to search for mutations in KRAS and identify those who can benefit from a targeted medicine called cetuximab. Doctors can now use the same test right away to commence treatment with trifluridine/tipiracil based on this evidence. The researchers have asked regulators to quickly incorporate the findings into guidelines which would make it standard to use the test for directing treatment with trifluridine/tipiracil.

“This is the first time we have a genomic marker already used in the clinic that can tell us whether a patient’s cancer will be sensitive or resistant to chemotherapy. We hope doctors will use this data to improve care for patients with advanced bowel cancer without delay,” said Professor Nicola Valeri, Honorary Professor of Gastrointestinal Oncology at Imperial College London and the ICR. “It will be difficult for some patients to find out that this last-line drug will not benefit them, but this test will mean they are able to avoid unnecessary side effects and have a better quality of life with advanced cancer. Fortunately, our findings also reveal a group of patients who see substantial benefits from taking this type of chemotherapy.”

Related Links:
Imperial College London

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.